CHERRY HILL, N.J., Sept. 11 Nuvilex, Inc. (OTC Bulletin Board: NVLX), announced today that Legacy Biotechnologies, Inc., its joint venture partner, has informed the company that Reme-Flu(TM) has been secured as the trade name for its homeopathic remedy for helping to prevent and treat flu-like symptoms resulting from influenza, including swine flu. The Reme-Flu(TM) formula consists of a two-part protocol. Part one contains clinically researched ingredients that have been shown to lessen both the duration and severity of flu symptoms. Part two consists of homeopathic sublingual tinctures that are focused on helping lessen respiratory symptoms commonly associated with the flu. This uniquely designed product's two-part protocol flu remedy provides a comprehensive and effective means for safely treating symptoms of the flu.
Homeopathy has a long and successful track record for helping to safely prevent and treat flu symptoms, including typical aches and pains that accompany the flu. During the last flu pandemic, occurring in 1918, homeopathy's performance was outstanding. According to a May, 1921 article in the Journal of the American Institute of Homeopathy, Dr. T A McCann stated that of 26,000 cases of the Spanish Flu treated allopathically (conventional treatment), the mortality rate was 28.2%. Conversely, of the 26,000 cases of Spanish Flu treated with homeopathy, the mortality rate was 1.05%. At the same time, statistics collected from Connecticut of over 6,600 cases of Spanish Flu treated homeopathically showed a mortality rate of less than 1%. During the same pandemic, the Homeopathic Medical Society reported the same impressive statistical findings for 1,500 cases treated with homeopathic remedies in the Washington D.C. area.
About Legacy Biotechnologies, Inc.
Legacy Biotechnologies, Inc. is an independent, privately owned firm specializing in research and development of nutraceutical and cosmeceutical formulations. They specialize in creating innovative and cutting-edge compounds that address all facets of health. Its president, Steve Kushner, has been working in this field for over 26 years and has created several original formulas that have been marketed both on a national basis and abroad. Mr. Kushner's experience allows Legacy Biotechnologies, Inc. to excel at all phases of the health and nutrition industry. In addition to research and development, Legacy Biotechnologies, Inc. is also well versed in the manufacturing process, procurement of raw materials, creation of promotional material, and marketing of products.
About Nuvilex, Inc.
Nuvilex, Inc. is an emerging healthcare consumer products company. The Company's lead products include: Last Shot Hangover Remedy(TM), a unique sugar-free, calorie-free and caffeine-free liquid formula designed to ease the symptoms of a hangover; Cinnergen(TM), which promotes a healthy glucose metabolism; Cinnechol(TM), designed to help maintain normal cholesterol levels and support normal cardiovascular function; and Infinitink (R), a permanent yet more easily removable tattoo ink. The Company's complete portfolio spans aesthetics, dermatology, environmental and nutraceutical products, all of which are designed to directly or indirectly improve human health. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., the developer of Infinitink (R). In conjunction with the merger, the Company changed its name to Nuvilex, Inc. from eFoodSafety.com. Please visit www.nuvilex.com for additional information on the Company.
Safe Harbor Statement
Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, the planned share exchange with Freedom2 Holdings, Inc., our ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.
Company Contact: Blair Barnes Senior Vice President and Chief Financial Officer Nuvilex, Inc. Ph: 856-433-6088 Email: email@example.com Press Contact: Pat Arcand Arcand & Madison Ph: 617-576-7777 Email: firstname.lastname@example.org
SOURCE Nuvilex, Inc.